Levaquin class action and individual lawsuits are now being filed on behalf of patients who allegedly suffered peripheral neuropathy and permanent nerve damage due to treatment with the fluoroquinolone antibiotic.
If you suffered peripheral neuropathy or nerve damage after taking this medication and are considering legal action, our attorneys can help you determine whether joining a Levaquin class action or filing an individual lawsuit would best serve your interest. To obtain a free review of your case, please contact the nationwide law firm of Bernstein Liebhard LLP by calling (888) 994-5118.
Levaquin was approved by the U.S. Food & Drug Administration (FDA) in 1996 and is indicated to treat serious bacterial infections like pneumonia and bubonic plague. The potential for Levaquin and other fluoroquinolone antibiotics to cause peripheral neuropathy was first noted in a case study published in the Annals of Pharmacotherapy in 2001. The report detailed 45 instances of the debilitating nerve disorder among people treated with the drugs. At least 84% of the cases were characterized as “severe,” while more than half persisted for a year or more.
It wasn’t until 2004 that information about peripheral neuropathy was added to all fluoroquinolone labels, including Levaquin. In 2013, however, the U.S. Food & Drug Administration (FDA) requested that the labels for Levaquin and other fluoroquinolones be updated to include stronger peripheral neuropathy and nerve damage warnings. Among other things, the agency expressed concern that the current labeling did not adequately describe the “potential rapid onset and permanence” of peripheral neuropathy symptoms. The FDA also required that statements characterizing peripheral neuropathy as a “rare” occurrence be removed.
When a Levaquin class action is filed, a single plaintiff is designated a class representative and will act on behalf of all members of the class. “Class members” include other individuals who have joined the suit and who allegedly suffered nearly identical injuries and damages. The class representative is given control over many important aspects of the case, including choice of attorney and whether or not to settle the claim. Any funds recovered as part of a Levaquin class action settlement would be shared equally among class members. However, the class representative would receive a larger share to compensate for their more extensive role in the case.
Compensation in a class action lawsuit might consist of refunds or rebates to reimburse consumers for purchasing Levaquin, as well as funds to establish a program to monitor their health. Patients who experienced peripheral neuropathy after taking Levaquin likely suffered a wider range of physical, financial and emotional damages. It’s unlikely that compensation from a class action settlement would make these plaintiffs whole. In such a case, fair compensation can only be obtained by filing an individual Levaquin lawsuit.
The attorneys at Bernstein Liebhard LLP are offering free legal reviews to individuals who may have been harmed by Levaquin or other fluoroquinolone antibiotics. Please call (888) 994-5118 to discuss your case with a member of our legal team today.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.